With a strong presence across major therapeutic markets, Cadila Pharma continues to redefine standards in diabetes management.


Diabetes is a chronic condition in which the body can't properly regulate blood glucose levels, often due to insulin resistance or insufficient insulin secretion. Uncontrolled blood sugar can cause severe complications in the heart, kidneys, nerves, and eyes. Managing diabetes requires a comprehensive approach that targets the factors that raise glucose levels.
Our therapeutic focus
Cadila Pharma combines essential therapies with next-generation pharmacological options to support complete and consistent metabolic control.




Key Brand
Humstard is a premixed suspension combining short-acting soluble insulin (30%) and intermediate-acting isophane insulin (70%). This dual-action formulation provides a rapid onset to manage post-meal glucose spikes alongside a sustained release that covers basal insulin needs for up to 24 hours.
Brand names are for reference purpose only and shall not be treated as an advertisement. Please consult a registered medical practitioner before taking any medication
Contact Us
Our Story
Businesses
Therapies
Corporate Identification No : U24231GJ1991PLC015132
©2026 Cadila Pharmaceuticals. All rights reserved